Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLLLydia Scarfò, Paolo Ghia, Gianluigi Reda et al.|Blood|2022Cited by 10
P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORTLydia Scarfò, Paolo Ghia, Silvia Heltai et al.|HemaSphere|2023Cited by 2
Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve StudyElisabetta Albi, Paolo Ghia, Lydia Scarfò et al.|Blood|2023Cited by 2
Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and SymptomsElena Crisà, Esther Natalie Olíva, Daniela Cilloni et al.|Blood|2024Cited by 0
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Esther Natalie Olíva, Daniela Cilloni et al.|Preprints.org|2025Cited by 0